IRX1, NPY and ZNF300 expression were significantly reduced in de novo MDS and AML patients, and only IRX1 and ZNF300 expression were associated with their gene methylation analyzed by targeted bisulfite sequencing. This evidence concerns the gene ZNF300 and myelodysplastic syndrome.